Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with dose selections of PEG-rhGH is scarce. The present study compar...

Full description

Bibliographic Details
Main Authors: Zhouhong Jiang, Xuefeng Chen, Guanping Dong, Yin Lou, Jianping Zhang, Xinran Cheng, Jiayan Pan, Wei Liao, Jinzhun Wu, Xiaodong Huang, Xianjiang Jin, Deyun Liu, Ting Zeng, Shunye Zhu, Qin Dong, Xiaoming Luo, Dan Lan, Lizhi Cao, Xingxing Zhang, Jing Liu, Mingjuan Dai, Manyan Zhang, Li Liu, Junhua Dong, Dongmei Zhao, Shaoqing Ni, Junfen Fu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
PEG-rhGH
GHD
IGF-1
dose
children
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.955809/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.955809/full

Similar Items